VeliparibInduced Toxicity in Cancer Patients: A Systematic Review and MetaAnalysis.
Cancer Invest
; 42(3): 260-273, 2024 Mar.
Article
in En
| MEDLINE
| ID: mdl-38588003
ABSTRACT
In this study, we investigate the veliparibinduced toxicity in cancer patients. Databases were searched for RCTs treated with veliparib. We found veliparib could increase the risk of hematologic and gastrointestinal toxicities. Anemia, neutropenia, thrombocytopenia, and nausea were the most common toxicities. Patients diagnosed with gastrointestinal tumors tend to have a higher risk of high-grade neutropenia; patients in the first-line setting tend to have a higher risk of high-grade anemia and neutropenia than those in the ≥ second line setting. Patients receiving higher dosage of veliparib tend to have a higher risk of all-grade anemia. Veliparib could also increase the risk of insomnia, myalgia, pneumonia, dyspnea, hyponatremia, and fatigue.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Benzimidazoles
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Cancer Invest
Year:
2024
Type:
Article
Affiliation country:
China